A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis. by Gourraud, Pierre-Antoine et al.
UCSF
UC San Francisco Previously Published Works
Title
A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles 
for autoantibody production in rheumatoid arthritis.
Permalink
https://escholarship.org/uc/item/32546691
Journal
Arthritis research & therapy, 9(2)
ISSN
1478-6354
Authors
Gourraud, Pierre-Antoine
Dieudé, Philippe
Boyer, Jean-Frédéric
et al.
Publication Date
2007
DOI
10.1186/ar2131
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Available online http://arthritis-research.com/content/9/2/R27Open AccessVol 9 No 2Research article
A new classification of HLA-DRB1 alleles differentiates 
predisposing and protective alleles for autoantibody production in 
rheumatoid arthritis
Pierre-Antoine Gourraud1, Philippe Dieudé2, Jean-Frédéric Boyer3,4, Leonor Nogueira5, 
Anne Cambon-Thomsen7, Bernard Mazières3,4, François Cornélis6, Guy Serre5, Alain Cantagrel3,4 
and Arnaud Constantin1,3,4
1Service d'Epidémiologie CHU Toulouse, INSERM, U558, Université Paul Sabatier Toulouse III, Faculté de Médecine, 37 allées Jules Guesde, 
Toulouse Cedex 7, 31073, France
2Service de Rhumatologie, CHU Bichat Claude-Bernard, 46 rue Henri Huchard, Paris, 75018, France
3GRCB40, UFR Sciences Médicales Rangueil, 1 avenue du Professeur Jean Poulhès, Toulouse Cedex 9, 31059, France
4Service de Rhumatologie, CHU Toulouse Rangueil, 1 avenue du Professeur Jean Poulhès, Toulouse Cedex 9, 31059, France
5Laboratoire de Biologie Cellulaire et Cytologie, CHU Toulouse Purpan, Place du Docteur Baylac, Toulouse cedex 9, 31059, France
6GenHotel, Genopole, 2 rue Gaston Crémieux, Evry Cedex, 91057, France
7INSERM, U558, Faculté de Médecine, 37 allées Jules Guesde, Toulouse Cedex 7, 31073, France
Corresponding author: Arnaud Constantin, constant@cict.fr
Received: 27 Nov 2006 Revisions requested: 2 Feb 2007 Revisions received: 5 Mar 2007 Accepted: 12 Mar 2007 Published: 12 Mar 2007
Arthritis Research & Therapy 2007, 9:R27 (doi:10.1186/ar2131)
This article is online at: http://arthritis-research.com/content/9/2/R27
© 2007 Gourraud et al., licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The HLA-DRB1 gene was reported to be associated with
anticitrullinated protein/peptide autoantibody (ACPA)
production in rheumatoid arthritis (RA) patients. A new
classification of HLA-DRB1 alleles, reshaping the shared
epitope (SE) hypothesis, was recently found relevant in terms of
RA susceptibility and structural severity.
We investigated the relevance of this new classification of HLA-
DRB1 SE+ alleles in terms of rheumatoid factor (RF) and ACPA
production in a sample of French RA patients.
We studied 160 early RA patients included in a prospective
longitudinal cohort of French Caucasian patients with recent-
onset arthritis. RF, anticyclic citrullinated peptide 2 (anti-CCP2)
and antideiminated human fibrinogen autoantibodies (AhFibA)
were assessed in all patients at inclusion. The HLA-DRB1 gene
was typed by PCR-sequence specific oligonucleotides probes
(PCR-SSOP), and SE+ alleles were classified into four groups
(S1, S2, S3P, S3D) according to the new classification.
The new classification of HLA-DRB1 SE+ alleles distinguishes
predisposing and protective alleles for RF, anti-CCP2 or AhFibA
production. The presence of S2 or S3P alleles is associated
with both RF, anti-CCP2 or AhFibA positivity, whereas the
presence of S3D or S1 alleles appears to be protective for RF,
anti-CCP2 or AhFibA positivity.
The new classification of HLA-DRB1 SE+ alleles is relevant in
terms of autoantibody production in early RA patients by
differentiating predisposing and protective alleles for RF or
ACPA production.
Introduction
Since early rheumatoid arthritis (RA) is often indistinguishable
from other inflammatory joint diseases, recent-onset inflamma-
tory synovitis poses a diagnostic and prognostic challenge to
rheumatologists [1]. The identification and validation of immu-
nologic and genetic markers with strong diagnostic and prog-
nostic value in early RA may help rheumatologists to meet this
challenge [2].Page 1 of 8
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ACPA = anticitrullinated protein/peptide autoantibody; AhFibA = antideiminated human fibrinogen autoantibodies; anti-CCP = anticyclic citrullinated 
peptide; ELISA = enzyme-linked immunosorbent assay; HLA = human leukocyte antigen; MHC = minor histocompatibility complex, PCR = polymer-
ase chain reaction; RA = rheumatoid arthritis; RF = rheumatoid factor; SE = shared epitope.
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antibodies (ACPAs) constitute relevant tools in the diagnosis
and prognosis of early RA. Citrulline is a nonstandard amino
acid, generated by post-translational modifications of several
proteins by deimination of arginine residues by peptidy-
larginine deiminases [3,4]. The citrulline moiety is the true
determinant in proteins recognized by antiperinuclear factor
[5], antikeratin antibodies [6], antifilaggrin antibodies [7], anti-
cyclic citrullinated peptide (anti-CCP) antibodies [8] and anti-
deiminated human fibrinogen autoantibodies (AhFibA) [9-11].
ACPAs may be detected in healthy individuals, years before
the onset of symptoms of RA [12,13], and may predict pro-
gression to persistent erosive arthritis or to RA in patients with
undifferentiated arthritis [14-16]. ACPAs are as sensitive as,
and more specific than, rheumatoid factor (RF) for early RA
diagnosis [17-19]. Furthermore, ACPAs represent a prognos-
tic factor for erosive disease in early RA [20-24].
Among genetic markers, the HLA-DRB1 gene has been
clearly involved in the pathogenesis of RA [25,26]. The asso-
ciation between HLA-Dw4 and RA was first reported in 1976
[27]. The development of HLA-DRB1 genotyping led to the
demonstration that different HLA-DR4 alleles were not equally
associated with RA and that several non-DR4 HLA–DRB1
alleles were also associated with the disease. The shared
epitope (SE) hypothesis, first proposed in 1987, represents an
approach to understand the molecular genetics of susceptibil-
ity to RA. The SE hypothesis assumes that HLA-DRB1 alleles
encoding a highly conserved amino acid sequence, known as
the SE – which is characterized by the RAA pattern at posi-
tions 72–74 of the third hypervariable region of different HLA-
DRβ1 chains – are associated with susceptibility to RA [28].
HLA-DRB1 alleles encoding the SE were then associated with
structural severity of RA [29] and have been more recently
associated with production of ACPAs [9,12,24,30-32].
As was done in previous attempts [33,34], du Montcel and
colleagues recently introduced a new classification of HLA-
DRB1 alleles that reconsiders the SE hypothesis [35]. In
terms of susceptibility to RA, this new classification suggests
that the risk of developing RA depends on whether the RAA
sequence occupies positions 72–74 but the risk is modulated
by the amino acids at position 71 (K confers the higher risk, R
an intermediate risk, A and E a lower risk) and at position 70
(Q or R confers a higher risk than D) [35-37] complexifying the
classical SE epitope classification based on the presence of
RAA in positions 72–74. In terms of structural severity of RA,
this new classification allowed the differentiation of predispos-
ing or protective alleles (two effects) – respectively character-
ized by the DRRAA or by the DERAA amino acid pattern at
positions 70–74 [36] – which was not possible using the clas-
sical SE epitope classification based on the only presence of
RAA in positions 72–74.
In the present study, we investigated the relevance of this new
classification of HLA-DRB1 alleles in terms of RF and ACPA
production in a cohort of French Caucasian patients with early
RA. Interestingly, the new classification of HLA-DRB1 alleles
allows the differentiation between predisposing and protective
alleles for autoantibody production.
Materials and methods
Patients
One hundred and sixty Caucasian outpatients were selected
from the Rangueil Midi-Pyrénées cohort, which involved
patients with early arthritis who attended the Rangueil Hospital
Department of Rheumatology between November 1992 and
December 1997, according to the following criteria: the Amer-
ican College of Rheumatology 1987 criteria for RA [38], dis-
ease duration <1 year from the first clinical manifestation of
RA, and age over 16 years.
Each individual included in the Rangueil Midi-Pyrénées cohort
signed an informed consent form. The protocol was initially
approved by the Committee for the Protection of Persons Par-
ticipating in Biomedical Research (French law 88–1138
December 20, 1988).
Detection of RF and ACPAs
Blood samples were collected at baseline, immediately centri-
fuged and stored at -80°C until assayed. RF was quantified by
nephelometry according to the manufacturer's recommenda-
tions (RF Reagent, IMMAGE immunochemistry system; Beck-
man Coulter, Inc., Fullerton, CA, USA). Anti-CCP2 antibodies
were detected by ELISA according to the instructions of the
manufacturer (IMMUNOSCAN RA; Euro-Diagnostica, Arn-
hem, The Netherlands). AhFibA were detected with a recently
developed inhouse ELISA, using in vitro deiminated human
fibrinogen as immunosorbent [9,10]. The cut-off points of the
two ELISAs were previously set so they reached the same
diagnostic specificity of 98.5%.
HLA-DRB1 genotyping and allele classification
Genomic DNA was extracted from ethylenediamine tetraace-
tic acid anticoagulated peripheral blood, using a standard pro-
teinase K digestion and phenol/chloroform extraction method,
in all patients at the time of inclusion. HLA-DRB1 typing and
subtyping were performed by a PCR-based method, using a
panel of sequence-specific oligonucleotide probes [36].
HLA-DRB1 alleles were pooled according to the new classifi-
cation proposed by du Montcel and colleagues [35,36].
Briefly, the HLA-DRB1 alleles were first divided into two
groups according to the presence or absence of the RAA
sequence at positions 72–74 and were denoted S and X alle-
les, respectively. The S alleles were subsequently divided into
four groups according to the amino acid at position 71: an
alanine (A), a glutamic acid (E), a lysine (K), or an arginine (R).
Different groups were thus defined in the new classification:Page 2 of 8
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all non-RAA patterns. Since an aspartic acid (D) at position 70
was reported to be protective against RA susceptibility in
comparison with a glutamine (Q) or an arginine (R) at the same
position [39], two additional groups were defined: S3D for
DRRAA, and S3P for QRRAA or RRRAA [35,36] (Table 1).
Statistical analysis
Agreements with Hardy–Weinberg equilibrium were tested
using Pearson's chi-square test and Fischer's exact test when
relevant. The association between the HLA-DRB1 gene poly-
morphism and RF or ACPAs was tested by comparing (by the
chi-square test or the exact Fisher test when relevant) the dis-
tribution of positive or negative patients for RF or anti-CCP2
antibodies or AhFibA among carriers and noncarriers for each
of the four groups of HLA-DRB1 alleles encoding the SE,
defined according to the new classification of HLA-DRB1 alle-
les (S1D, S2D, S3P, S3D). Odds and odds ratios (95% con-
fidence intervals) were also calculated. The dose effect was
investigated for alleles positively or negatively associated with
immunological markers using tests for the trend of the log
odds.
Statistical analyses were performed using Stata Statistical
Software (release 9.1 SE; Stata Corporation, College Station,
TX, USA). All P values were two-sided, and P < 0.05 was con-
sidered statistically significant after correcting when relevant
for multiple testing according to the Benjamini–Yekutieli 2001
method.
Results
Demographic and immunologic characteristics of RA 
patients
The main baseline demographic and immunologic characteris-
tics of the 160 patients with early RA included in the present
study were the following: 120 women (75%) and 40 men
(25%); mean (± standard deviation) age, 50.31 (± 14.03)
years; mean (± standard deviation) disease duration, 0.55 (±
0.02) years; number (%) RF-positive, 110/160 (68.75%);
number (%) anti-CCP2 antibody-positive, 110/160 (68.75%);
and number (%) AhFibA-positive, 108/160 (67.25%).
Allele frequencies for HLA-DRB1 polymorphisms
The frequencies of HLA-DRB1 alleles, classified into five
groups according to the new classification, were as follows:
S1, 59/320 (18.4%); S2, 65/320 (20.3%); S3D, 42/320
(13.3%); S3P, 89/320 (27.81%); and X, 65/320 (20.31). No
departures from Hardy–Weinberg equilibrium were found for
HLA-DRB1 alleles classified into the five groups (P = 0.7171;
10 degrees of freedom).
Relationship between HLA-DRB1 allele carrier status 
and RF status
Table 2 presents the status for RF among patients carrying the
different HLA-DRB1 alleles encoding the SE classified into
four groups according to the new classification. On the one
hand, S2 carriers had a higher frequency of RF in comparison
with noncarriers (odds ratio > 1 and P < 0.05). On the other
hand, S3D and S1 carriers had a lower frequency of RF in
comparison with noncarriers (odds ratio < 1 and P < 0.05).
These results support the hypothesis of an association
between HLA-DRB1 gene polymorphisms and RF, and the
results point out the interest of the new classification of HLA-
DRB1 alleles in order to differentiate predisposing and protec-
tive alleles for RF production in early RA.
Relationship between HLA-DRB1 allele carrier status 
and anticitrullinated protein/peptide autoantibody 
status
Table 3 presents the status for anti-CCP2 antibodies or
AhFibA among patients carrying the different HLA-DRB1 alle-
les encoding the SE classified into four groups according to
the new classification. On the one hand, S2 and S3P carriers
had a higher frequency of anti-CCP2 antibodies or AhFibA in
comparison with noncarriers (odds ratio > 1 and P < 0.05).
On the other hand, S3D and S1 carriers had a lower frequency
of anti-CCP2 antibodies or AhFibA in comparison with noncar-
riers (odds ratio < 1 and P < 0.05).
The interest of the new classification is that both predisposing
and protective alleles for the production of ACPA are found.
The effects remain significant after correction for multiple test-
ing using the Benjamini–Yekutieli 2001 procedure imple-
mented in STATA 9.0 (State Corporation), which corrects for
an overall false discovery rate (5% here) (see Table 3). In the
present analysis based on carrier status, a potential bias may
be introduced by the presence of an adverse effect allele in the
control group. In the analysis of the S2 effect, for example, the
association may be overestimated by the presence of S3D
carriers in the control group (noncarrier of S2). The effect of
S2 may similarly be underestimated by the presence of S3P
carriers. After controlling for the adverse effect of S3D and S1
in the analysis of S2, the association with the positivity of
Ahfiba remains significant (P < 0.05). After controlling for the
adverse effect of S2 and S3P in the analysis of S3D, the asso-
ciation with negativity of anti-CCP2 remained significant.
These results support the hypothesis of an association
between HLA-DRB1 gene polymorphisms and ACPAs, and
point out the interest of the new classification of HLA-DRB1
alleles in order to differentiate predisposing and protective
alleles for ACPA production in early RA.
Discussion
The results of the present study confirm previous evidence of
an association between HLA-DRB1 gene polymorphisms and
RF or ACPAs in RA. Furthermore, the results point out the
interest of the new classification of HLA-DRB1 alleles in orderPage 3 of 8
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HLA–DRB1 amino acid sequence for alleles observed among rheumatoid arthritis patients and their classification according to du 
Montcel and colleagues
HLA-DRB1 allele Amino acid position Classification of du Montcel and colleagues
69 70 71 72 73 74 75 76
HLA-DRB1*0101 E Q R R A A V D S3P
HLA-DRB1*0102 - Q R R A A - - S3P
HLA-DRB1*0103 - D E R A A - - S1
HLA-DRB1*03 - - K - G R - - X
HLA-DRB1*0401 - Q K R A A - - S2
HLA-DRB1*0402 - D E R A A - - S1
HLA-DRB1*0403 - - - - - E - - X
HLA-DRB1*0404 - Q R R A A - - S3P
HLA-DRB1*0405 - Q R R A A - - S3P
HLA-DRB1*0407 - - - - - E - - X
HLA-DRB1*0408 - Q R R A A - - S3P
HLA-DRB1*0411 - - - - - E - - X
HLA-DRB1*07 - D - - G Q - - X
HLA-DRB1*08 - D - - - L - - X
HLA-DRB1*0901 - R - - - E - - X
HLA-DRB1*1001 - Q R R A A - - S3P
HLA-DRB1*1101 - D R R A A - - S3D
HLA-DRB1*1102 - D E R A A - - S1
HLA-DRB1*1103 - D E R A A - - S1
HLA-DRB1*1104 - D R R A A - - S3D
HLA-DRB1*12 - D R R A A - - S3D
HLA-DRB1*1301 - D E R A A - - S1
HLA-DRB1*1302 - D E R A A - - S1
HLA-DRB1*1303 - D K R A A - - S2
HLA-DRB1*1323 - D E R A A - - S1
HLA-DRB1*1401 - R - - - E - - X
HLA-DRB1*1402 - Q R R A A - - S3P
HLA-DRB1*1404 - R - - - E - - X
HLA-DRB1*15 - Q A R A A - - S1
HLA-DRB1*16 - D R R A A - - S3D
In the du Montcel and colleagues classification [35], the HLA–DRB1 alleles were first divided into two groups according to the presence or 
absence of the RAA sequence at positions 72–74, which denote S and X alleles (respectively shared epitope and nonshared epitope alleles). The 
S alleles were subsequently divided into four groups according to the two first amino acids at positions 70 and 71 (boldface): S1 for ARAA and 
ERAA, S2 for KRAA, S3 for RRAA (divided into S3P for QRRAA and S3D for DRRAA according to position 70), and X for all non-RAA motifs. The 
conventional classification of the amino acids was used, here divided into three biochemical subgroups, as follows: group 1 = G for glycine, A for 
alanine, V for valine, L for leucine (aliphatic amino acids (nonpolar hydrophobic)); group 2 = K for lysine, R for arginine (basic amino acids (polar 
and positively charged)); group 3 = E for glutamic acid, Q for glutamine (the amide corresponding to E), D for aspartic acid, and N for asparagine 
(the amide corresponding to D) (acidic amino acids and corresponding amides are very hydrophilic; acidic amino acids are polar and negatively 
charged at physiologic pH, amides are polar and uncharged, and not ionizable) [36].Page 4 of 8
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The results of the present study confirm previous evidence of
an association between HLA-DRB1 gene polymorphisms and
autoantibody production in RA. We found a positive associa-
tion between carriers of HLA-DRB1*SE+ alleles (HLA-
DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0405, HLA-
DRB1*0408, HLA-DRB1*1001) and RF or ACPA production,
while we did not find any negative association between carri-
ers of HLADRB1*SE- alleles and RF or ACPA production (data
not shown). An association between HLA-DRB1*04 or HLA-
DRB1*SE+ alleles and RF has been reported in some studies
[12,30,40] but rejected in others [12,32,41]. An association
between HLA-DRB1*01, HLA-DRB1*04 or HLA-DRB1*SE+
alleles and ACPAs was more constantly reported in European
or North American RA patients [9,12,24,30,32,40,42-45].
Since the presence of RF was strongly correlated with that of
ACPAs in most of these studies, several groups investigated
whether these associations between HLA-DRB1 gene poly-
morphisms and RF or ACPAs were independent. These stud-
ies showed that the association between HLA-DRB1*SE+
alleles and ACPAs is constantly stronger than the association
between HLA-DRB1*SE+ alleles and RF. Furthermore, they
suggested that the association between HLA-DRB1*SE+ alle-
les and ACPAs is independent of the RF status, leading to the
conclusion that HLA-DRB1*SE+ alleles are primarily associ-
ated with the presence of ACPAs, but not with the presence
of RF [24,32,41].
The results of the present study indicate the interest of the
new classification of HLA-DRB1 alleles to differentiate predis-
posing and protective alleles for autoantibody production in
early RA. This new classification, which is based on an initial
split of HLA-DRB1 alleles into two groups according to the
presence (S alleles) or absence (X alleles) of the RAA
sequence at positions 72–74, subsequently divides S alleles
into four groups according to the amino acids at positions 71
and 70. Most of the previous studies, based on the common
classification, identified HLA-DRB1*101, HLA-DRB1*0401,
HLA-DRB1*404 and HLA-DRB1*1001 as predisposing alle-
les for ACPA production in RA, with a significant dose effect
in patients carrying two of these predisposing alleles
[9,12,32,44]. Only a few association studies reported an HLA-
DRB1 allelic protective effect for ACPA production in RA. In
these studies, HLA-DRB1*03 was associated with ACPA-
negative RA and decreased titers of ACPAs, even in the pres-
ence of an SE allele [32,45]. In the new classification of HLA-
DB1 allelles, HLA-DRB1*03 is not taken into account sepa-
rately since it is classified into the X group of alleles, which do
not encode the SE sequence. In the present study, comple-
mentary analysis did not show any association between HLA-
DRB1*03 carrier status and RF or ACPA production (data not
shown). The use of the classification by du Montcel and col-
leagues suggests a risk hierarchy in ACPA production in early
RA patients: the S2 (KRAA at positions 71–74) and S3P
(QRRAA or RRRAA at positions 70–74) alleles conferring
predisposition, while the S1 (ARAA or ERAA at positions 71–
74) and S3D (DRRAA at positions 70–74) alleles confer pro-
Table 2
Relationship between HLA-DRB1 allele carrier status and rheumatoid factor status in French patients with early rheumatoid 
arthritis
Carrier status Odds ratio (95% confidence interval) P P for trend
Yes No
S1 carrier
Rheumatoid factor-positive 31 (55.4) 79 (75.9) 0.39 (0.19–0.83) 0.0118 0.0051*
Rheumatoid factor-negative 25 (44.6) 25 (24.0)
S2 carrier
Rheumatoid factor-positive 49 (83.1) 61 (60.4) 3.21 (1.39–7.9) 0.0028* 0.0049*
Rheumatoid factor-negative 10 (16.9) 40 (39.6)
S3P carrier
Rheumatoid factor-positive 57 (74.0) 53 (63.9) 1.61 (0.78–3.38) 0.1766 0.4478
Rheumatoid factor-negative 20 (26.0) 30 (36.1)
S3D carrier
Rheumatoid factor-positive 19 (51.4) 91 (74.0) 0.37 (0.16–0.86) 0.0145 0.0209
Rheumatoid factor-negative 18 (48.6) 32 (26.0)
Data presented as n (%). Status for rheumatoid factor among 160 patients with early rheumatoid arthritis, carrying the different HLA-DRB1 alleles 
encoding the shared epitope classified into four groups according to the new classification. Odds ratios, 95% alpha-risk confidence interval and 
P value for exact Fisher test. The dose effect was investigated for alleles positively or negatively associated with immunological markers using 
tests for trend of the log odds. *Significant after correcting for multiple testing according to the Benjamini–Yekutieli 2001 method at an overall 
critical P value of 5%.Page 5 of 8
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 No 2    Gourraud et al.tection, in comparison with X (non-RAA patterns at positions
72–74).
The use of the new classification of HLA-DRB1 alleles pro-
posed by du Montcel and colleagues seems to provide differ-
ent pictures of the relative contribution of the HLA-DRB1
locus to RA pathogenesis. This relative contribution is not
restricted to ACPA production, but also includes risk hierarchy
for RA susceptibility and structural severity [35-37].
Trying to understand the findings of genetic association/link-
age studies in complex multifactorial diseases, such as RA, in
light of the amino acid alignment of a protein encoded by a
candidate gene remains a challenging task. In fact, the interac-
tions between HLA-DRB1 molecules and citrullinated pep-
tides may impact RA pathogenesis in several ways. For
example, a previous study conducted in DR4-IE transgenic
mice demonstrated that the conversion of arginine to citrulline
at the peptide side-chain position interacting with the SE sig-
nificantly increases peptide–MHC affinity and leads to the
activation of CD4+ T cells, suggesting that HLA-DRB1 alleles
encoding the SE could initiate an autoimmune response to cit-
rullinated self-antigens [46].
Conclusion
Although no formal conclusions on causality can be drawn
from the present association study, our findings indicate the
interest of this new classification of HLA-DRB1 alleles in order
Table 3
Relationship between HLA-DRB1 allele carrier status and anticitrullinated protein/peptide autoantibody status in French patients 
with early rheumatoid arthritis
Carrier status Odds ratio (95% confidence interval) P P for trend
Yes No
S1 carrier
CCP2-positive 32 (57.1) 78 (75.0) 0.44 (0.21–0.94) 0.0312 0.0134
CCP2-negative 24 (42.9) 26 (25.0)
AhFibA-positive 31 (55.4) 77 (74.0) 0.43 (0.21–0.91) 0.0213 0.0113
AhFibA-negative 25 (44.6) 27 (26.0)
CCP2-positive
CCP2-negative 49 (83.1) 61 (60.4) 3.21 (1.39–7.9) 0.0028* 0.0049*
AhFibA-positive 10 (16.9) 40 (39.6)
AhFibA-negative 50 (84.8) 58 (57.4) 4.12 (1.75–10.49) 0.0004* 0.0003*
CCP2-positive 9 (15.2) 43 (42.6)
S3P carrier
CCP2-positive 61 (79.2) 49 (59.0) 2.65 (1.24–5.74) 0.0066* 0.0014*
CCP2-negative 16 (20.8) 34 (41.0)
AhFibA-positive 61 (79.2) 47 (56.6) 2.92 (1.38–6.32) 0.0025* 0.0035*
AhFibA-negative 16 (20.8) 36 (43.4)
S3D carrier
CCP2-positive 17 (45.9) 93 (75.6) 0.27 (0.12–0.63) 0.0011* 0.0009*
CCP2-negative 20 (54.1) 30 (24.4)
AhFibA-positive 19 (51.4) 89 (72.4) 0.4 (0.18–0.93) 0.0266 0.0145
AhFibA-negative 18 (48.6) 34 (27.6)
Data presented as n (%). Status for anticyclic citrullinated peptides (anti-CCP2) antibodies or antideiminated human fibrinogen autoantibodies 
(AhFibA) among 160 patients with early rheumatoid arthritis, carrying the different HLA-DRB1 alleles encoding the shared epitope classified into 
four groups according to the new classification. Odds ratios, 95% alpha-risk confidence interval and P value for exact Fisher test. The dose effect 
was investigated for alleles positively or negatively associated with immunological markers using tests for trend of the log odds. *Significant after 
correcting for multiple testing according to the Benjamini–Yekutieli 2001 method at an overall critical P value of 5%.Page 6 of 8
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